effectively treat multidrug-resistant A. baumannii (MDR-AB) infections has not yet been realized. Pharmaceutical companies that were historically at the forefront of new antimicrobial discovery have abandoned the field entirely. As infectious diseases experts stated in a publication titled The Seven Ways to Preserve the Miracle of Antibiotics the "pipeline is sparse, the problem is global, and prognosis is poor." [5] Another strategy described to combat resistance, is the use of antimicrobial stewardship programs (ASPs) to ensure the appropriate use of existing and new antibiotics and identify suitable alternative strategies among available antimicrobial agents. ASPs have become of paramount importance to recommend antibiotics to effectively treat MDR-AB infections.
The increasing lack of clinically effective antimicrobials to treat A. baumannii infections has led to the worldwide resurrection of polymyxins, particularly polymyxin E (colistin). Despite the agent's prevalent use, concerns exist regarding dosing, toxicity, and the emergence of resistance. This has led clinicians to reevaluate other "older" agents for the treatment of MDR-AB. Minocycline is one such "old drug," available both intravenously (IV) and orally (PO) with Food and Drug Administration (FDA) approval for the treatment of infections caused by Acinetobacter spp. [6] . The IV formulation was voluntarily withdrawn from the US market in 2005 and reintroduced to the US market in May 2009. Currently, there is a paucity of contemporary data on the clinical use of minocycline for the treatment of MDR-AB infections [7] . The objective of this study is to describe an ASP's evaluation of IV minocycline in hospitalized patients for the treatment of MDR-AB infections.
METHODS

Susceptibility Analysis
Prior to this evaluation of clinical outcomes, 67 MDR-AB isolates from unique patients hospitalized in 2009 at The Ohio State University Wexner Medical Center (OSUWMC) were tested for minocycline minimum inhibitory concentrations (MICs) using an Etest (Biomerieux, Marcy l'Etoile, France) according to the current Clinical and Laboratory Standards Institute (CLSI) interpretative criteria; MIC ≤ 4 mg/L is susceptible, 8 mg/L is intermediate, and ≥16 mg/L is resistant [8] . Our analysis determined that 32 (48%) isolates were susceptible to minocycline. Minocycline was susceptible or intermediate in 47 (70%) of the 67 isolates compared to 100% resistance to tetracycline. Tetracycline breakpoints are MIC ≤4 mg/L susceptible, 8 mg/L is intermediate, and ≥16 mg/L is resistant. Tigecycline was reported as susceptible in 61/67 (94%) isolates. Notably, minocycline was susceptible in 4 of 6 isolates that demonstrated tigecycline with an MIC ≥ 8 mg/L [7] . For tigecycline, the US Food and Drug Administration breakpoint recommendation for Enterobacteriaceae was used (susceptible, MIC ≤ 2 mg/L; intermediate, MIC = 4 mg/L; resistant MIC ≥ 8 mg/L). Based on these findings, OSUWMC's ASP recommended the addition of IV minocycline to formulary and routine susceptibility testing for all MDR-AB isolates as of September 2010.
Study Population
This is a retrospective evaluation of all hospitalized adult patients admitted between 1 September 2010 to 31 March 2013 who received IV minocycline for a positive MDR-AB culture at OSUWMC, a 1,234-bed tertiary-care facility located in Columbus, Ohio. The study was approved by the Office of Responsible Research Practices Institutional Review Board, with a waiver of consent granted. All patients received an IV minocycline regimen of 100 mg twice daily. Only the first episode per study period was analyzed.
Inclusion/Exclusion Criteria
Patients were included if all of the following criteria were met: (1) age ≥18 and <89 years, (2) culture positive for MDR-AB defined as nonsusceptible to ≥1 agent in ≥3 antimicrobial categories (excluding minocycline) [9] , (3) culture with in vitro susceptibility to minocycline, (4) minocycline administered within 72 hours of the onset of MDR-AB infection, and (5) receipt of minocycline for ≥48 hours. Pneumonia was defined as having signs and symptoms of fever or leukocytosis/leukopenia with an infiltrate on chest radiograph and a positive respiratory culture for MDR-AB [10] . Bloodstream infection (BSI) was defined as a positive blood culture for MDR-AB in the presence of systemic inflammatory signs and symptoms [11] . Complicated intra-abdominal infection was diagnosed as a positive culture for MDR-AB from the abdomen in the presence of gross purulence [12] . Osteomyelitis was diagnosed by imaging, presence of systemic inflammatory signs and symptoms, elevated C-reactive protein, and a positive culture for MDR-AB from the bone. A wound infection was defined as a positive culture for MDR-AB with purulent drainage. A urinary tract infection (UTI) was diagnosed by a positive urine analysis consistent with an active infection and a positive culture for MDR-AB from the urine. Additionally, patients with a positive culture for MDR-AB without active inflammation or systemic signs and symptoms attributable to the culture site were determined to be colonization and were not included in this study. Patients were excluded if any of the following criteria were met: (1) incarcerated, (2) pregnant, or (3) the pathogen was resistant to minocycline.
Data
Demographic and clinical outcome data were collected from the patient's electronic medical record and OSUWMC's Information Warehouse (IW). The data included age, sex, hospital service, Charlson comorbidity index [13] , APACHE (acute physiology and chronic health evaluation) II score [14] duration of hospitalization prior to culture collection, Infectious Diseases (ID) consult, intensive care unit (ICU) admission and length of stay, ICU admission at the time of culture collection, mechanical ventilation status at culture collection, microbiologic data, antibiotics administered, treatment duration, and site of infection. The APACHE II score was defined as the worst physiological score calculated during the initial 24 hours after culture collection. Community-acquired was defined as an infection occurring <48 hours from hospital admission. Hospital-acquired was defined as an infection occurring ≥48 hours from hospital admission. Treatment information included all antimicrobials administered for the MDR-AB infection. Concomitant therapy with ampicillin/sulbactam, IV or inhaled colistin, tigecycline, or doripenem was considered combination therapy, if administered within 72 hours of the positive culture, for ≥48 hours concomitant with minocycline, and the organism was also susceptible to both agents. The dosing frequency of IV colistin was adjusted per protocol using the Cockcroft Gault equation to calculate the creatinine clearance (Cl CR ): ≥50 mL/min (3.5 mg/ kg every 12 hours), ≥20-49 mL/min (3.5 mg/kg every 24 hours), ≤19 mL/min (3.5 mg/kg every 48 hours), hemodialysis or peritoneal dialysis (2.5 mg/kg every 48 hours), and continuous renal replacement therapy (3.5 mg/kg every 12 hours). All patients received a loading dose of colistin at 5 mg/kg, regardless of renal function. Inhaled colistin was dosed at 75 mg every 12 hours.
The primary outcome was clinical success, defined as complete or partial resolution of the signs and symptoms attributable to the MDR-AB infection without need for escalation of antimicrobials while on minocycline. Clinical failure was defined as the persistence of signs and symptoms attributable to the MDR-AB infection and the need for additional antimicrobials. Patients who died while receiving minocycline or had persistent signs and symptoms consistent with infection were considered clinical failures.
Secondary clinical outcomes included microbiologic eradication, recurrence of infection, length of hospital stay (LOS), infection-related LOS, infection-related mortality, 30-day readmission, and adverse events related to minocycline as documented in the chart. Microbiologic success was defined as eradication of MDR-AB in any follow-up cultures from the primary source of infection during treatment. Presumed microbiologic eradication was defined as resolution of signs and symptoms attributable to infection in the absence of followup cultures from the primary site of infection. Microbiologic failure was defined as persistence of MDR-AB in any follow-up cultures from the primary source of infection during treatment. LOS was calculated as the difference between admission and the discharge date. Infection-related LOS was calculated as the difference between initiation of antimicrobial administration for the MDR-AB infection and discontinuation or discharge date, whichever was sooner. Infection-related mortality was defined as death occurring in the presence of persistent clinical signs, microbiologic evidence of MDR-AB infections and no other plausible cause of death other than MDR-AB infection based on record review by an ID physician (J. E. M.). Thirty-day readmission was defined as hospital readmission within 30 days of hospital discharge. Adverse events attributed to minocycline required documentation in the electronic medical record. All patients with infections due to MDR-AB were placed in contact isolation.
Microbial Identification and Susceptibility Testing
The MicroScan Walkaway system (BD Diagnostic Systems, Sparks, MD) was used for identification and susceptibility testing of A. baumannii isolates. Antimicrobials routinely tested include amikacin, ampicillin/sulbactam, cefepime, ciprofloxacin, gentamicin, tetracycline, tobramycin, and trimethoprim/sulfamethoxazole. Clinical and Laboratory Standards Institute (CLSI) interpretative criteria were used to determine susceptibilities. CLSI colistin interpretative criteria for Acinetobacter spp. are susceptible (≤2 mg/L) and resistant (≥4 mg/L). Minocycline, colistin, and tigecycline susceptibilities were determined by Etest (Biomerieux, Marcy l'Etoile, France).
Statistical Analysis
Descriptive statistics only were performed. Data are presented as number (%) or median [interquartile range, IQR] as appropriate.
RESULTS
During the study period, 55 patients were identified for study inclusion. The minimum inhibitory concentration (MIC) distribution for minocycline is presented in Figure 1 . Baseline patient demographics are described in Table 1 . Overall, the median age was 56 (23-85) years, 65% were male with a median Charlson score of 3 (0-10), and median APACHE II score at the onset of infection of 21 (4-41). Forty-five (82%) patients received care from a medicine service. Primary infection site included: 32 (58%) respiratory, 10 (18%) blood, 3 (5%) peritoneal fluid, 4 (7%) respiratory + blood, 2 (4%) wound, 2 (4%) bone, and 2 (4%) urine. The majority of infections (65%) were acquired at OSUWMC with a median length of stay of 14 (1-60) days prior to culture collection. Twenty-five (45%) patients had an ID consult obtained within 10 days [2-55] of hospital admission. Forty-seven (85%) patients were admitted to the ICU for a length of stay of 18 (2-78) days. Thirty-nine (71%) patients required mechanical ventilation for 6 (2-29) days.
Antibiotic Regimens
Patients were treated with one of the following antibiotic regimens: minocycline monotherapy (3); and in combination with minocycline was: IV colistin (19) , doripenem + IV colistin (9), ampicillin/sulbactam + IV colistin (7), doripenem + inhaled colistin (4), ampicillin/sulbactam (3), ampicillin/sulbactam + doripenem + IV colistin (3), doripenem (2), ampicillin/ sulbactam + doripenem (2), ampicillin/sulbactam + inhaled colstin (1), inhaled colistin (1), ampicillin/sulbactam + IV colistin + inhaled colistin (1) . Overall the median duration of minocycline therapy was 9 days (2-35 days); ≤3 days n = 12, 4-7 days n = 8, 8-14 days n = 24, ≥15 days n = 11, with 42 (76%) patients receiving a 200 mg loading dose. No patient had any documented adverse events deemed to be attributable to minocycline. The doses of all concomitant antibiotics were based on OSUWMC guidelines.
Clinical and Microbiologic Response
The clinical and microbial responses to therapy are summarized in Table 2 . Clinical success was achieved in 40 (73%) patients treated with minocycline either alone or in combination. The median Apache II score among survivors was 20 . Repeat cultures to determine microbiological eradication were obtained in 31 (56%) patients. Overall, 43 (78%) patients demonstrated a documented or presumed microbiologic eradication, and 12 (22%) patients experienced microbiologic failure. Three (7%) of the 43 patients with documented or presumed microbiologic eradication subsequently experienced a clinical failure. All 3 isolates had a minocycline MIC = 3 mg/L.
Clinical Failures
Fifteen (27%) patients experienced clinical failure; 1 survived and 14 died secondary to the MDR-AB infection (Table 3 ). Twelve (86%) patients had pneumonia and 2 (14%) had pneumonia and bacteremia. The median age of all failures was 68 (27-85) years with an APACHE II score of 31 (17-41). Of the 14 nonsurvivors, 8 (57%) patients had an ID consult obtained within 11 (1-55) days of hospital admission. Thirteen (93%) patients were admitted to the ICU for a length of stay of 32 (5-75) days; and all 13 patients concomitantly received mechanical ventilation for 12 (2-28) days. The median duration of minocycline was 9 (2-35) days. The median baseline MIC to minocycline was 3 mg/L (1.5-4); there were no MIC's obtained on subsequent isolates. All patients received minocycline in combination with an additional active antimicrobial and the majority (57%) received IV colistin in combination with minocycline.
30-day Readmissions
One (2%) patient was readmitted for a MDR-AB infection 16 days post discharge secondary to worsening respiratory status. For the first episode of MDR-AB infection, the patient received 14 days of minocycline plus IV colistin and experienced clinical cure with presumed microbiologic eradication. The minocycline MIC was 4 mg/L. On readmission, the patient had respiratory culture due to MDR-AB and received IV and inhaled colistin and doripenem for 14 days. The minocycline MIC was then 6 mg/L with an intermediate susceptibility interpretation. This patient achieved clinical success and was subsequently discharged. ID was consulted for both episodes of MDR-AB infection.
DISCUSSION
This study represents the largest evaluation of hospitalized patients treated with IV minocycline alone or in combination for serious MDR-AB infections. Overall, 40 (73%) patients achieved clinical success and 43 (78%) patients demonstrated documented or presumed microbiologic eradication. Notably, the infection-related mortality rate was 25%. Among those who expired, all were critically ill with a median APACHE II score of 31 during an ICU admission, receiving mechanical ventilation.
The clinical and microbiologic response to minocycline alone or in combination is both significant and encouraging as the rate of MDR-AB continues to increase in the hospital setting. MDR-AB is an organism that poses a serious threat to public health due to the lack of effective antimicrobials. The successful treatment of MDR-AB often involves the use of ≥2 agents; however, the most effective combination therapy remains unknown.
Historically, ampicillin/sulbactam, carbapenems, and aminoglycosides had demonstrated efficacy in the treatment of A. baumannii. Ampicillin/sulbactam was associated with favorable patient outcomes. In a randomized, prospective study of patients with ventilator-associated pneumonia (VAP) caused by MDR-AB, patients were randomized to receive 1 of 2 ampicillin/sulbactam regimens (18/9 grams vs 24/12 grams) [15] . The authors found no differences in clinical improvement between the groups (66.7% vs 64.3%, respectively). In addition, microbiological success was achieved in 77.8% of the study population with a 14-day mortality rate of 25.9%. Carbapenems alone, or administered in combination with other antimicrobials, have been regarded as therapeutic agents of choice for MDR-AB infections [16, 17] . In addition, bactericidal synergy has been demonstrated in vitro with carbapenems when combined with sulbactam, colistin, and tigecycline [18] . Colistin demonstrates activity against A. baumannii, but had been reserved as a last line antibiotic. Falagas and colleagues reported positive results with colistin in 258 critically ill patients with multidrug-resistant gram-negative infections with the majority due to MDR-AB [19] . Improved clinical outcomes were demonstrated in patients receiving colistin monotherapy or colistin-meropenem combination with a clinical cure observed in 79.1% of patients. Recently, Lesho and colleagues describe MDR-AB isolates resistant to colistin. Interestingly, their isolates were susceptible to minocycline but had varying susceptibility to tigecycline [20] .
Tigecycline exhibits broad antibacterial activity, including A. baumannii, although it is not approved for the treatment of Acinetobacter infections. In a retrospective analysis of 25 patients with MDR-AB VAP and/or bacteremia treated with tigecycline, 21 (84%) and 12 (48%) patients demonstrated clinical resolution and microbial eradication, respectively. The authors observed 4 recurrences of VAP, but all subsequently demonstrated successful outcomes. Notably, a tigecycline resistant isolate developed during therapy, which was concerning and has been demonstrated in other studies [21] .
Antimicrobial stewardship programs represent an important component in the management of MDR-AB infections. These programs consisting of ID physicians and pharmacists can play a critical role in recommending effective treatment for A. baumannii infections. The most important consideration in determining appropriate therapy is an individual institution's antimicrobial susceptibility pattern. Unfortunately at OSUWMC, antimicrobial susceptibilities against A. baumannii to the most commonly used agents have dramatically decreased in recent years. From 2002 to 2012, ampicillin/sulbactam susceptibilities decreased from 96% to 65%, imipenem from 100% to 48%, and amikacin from 98% to 54%. From 2009 to 2012, tigecycline susceptibilities decreased from 98% to 44%, whereas minocycline and colistin susceptibilities were stable at 70% and 98%, respectively. These decreasing susceptibilities combined with increasing colistin use led OSUWMC's ASP to evaluate the potential use of IV minocycline for treating A. baumanii infections. A 2-step approach consisted of an initial microbiological assessment of our A. baumannii isolates followed by a formulary addition of IV minocycline and subsequent evaluation of patient outcomes as stated herein. In the initial study, 5 patients received minocycline in combination with ampicillin/sulbactam or colistin for pneumonia (n = 3), bacteremia (n = 1), and a skin and soft tissue infection (n = 1). The median treatment duration, length of stay, and infectionrelated LOS were 10, 34, and 21 days, respectively. All patients had a microbiologic cure, and 4 had clinical success [7] . In addition, minocycline continues to be the only antibiotic with the exception of colistin to retain ≥70% susceptibility against A. baumanni on our antibiogram. Based on these data, our empiric recommended combination therapy is IV minocycline plus IV colistin for the treatment of A. baumannii infections.
Recently published clinical experience with IV minocycline for the treatment of MDR-AB infections is limited to in vitro evaluations and small case series. Importantly, these studies have consistently demonstrated minocycline susceptibility of The majority of patients received combination therapy; however, clinical response rates did not differ between the minocycline monotherapy group (81.8%) compared to the minocycline combination therapy group (80%). In our study, comparisons between the various treatment groups were not performed due to the limited number of patients in each group. The answer regarding the most effective and safe regimen for the treatment of MDR-AB infections remains unknown. Currently, there are concerns with ampicillin/sulbactam due to increasing resistance and the dosing frequency needed to provide adequate high concentrations of sulbactam. Carbapenems used in combination have historically resulted in positive clinical outcomes, but resistance is increasing; our institution is now at only 48% susceptible. Colistin retains susceptibility against A. baumannii, but issues of appropriate dosing, toxicities, and resistance remain. Minocycline represents an attractive option in the treatment of MDR-AB infections as susceptibilities remain high, conversion from IV to oral therapy is available, and toxicity is relatively limited.
There are several limitations to our study. First, the study is a retrospective, observational study, and it was conducted at a single center with a small sample size. Second, patients were analyzed retrospectively, creating the possibility of information bias. Finally, most patients received IV minocycline in combination with a second active agent; therefore, the efficacy of minocycline monotherapy could not be determined.
The prevalence of healthcare-associated MDR-AB infections continues to increase globally. The reintroduction of IV minocycline provides an additional agent in a limited armamentarium for treating MDR-AB. ASPs and physicians must be aware of the potential option to use minocycline as for many patients this agent may represents a last line therapy. Because the optimal treatment has not yet been established, additional studies are necessary to properly assess the role of minocycline in optimizing outcomes in patients with MDR-AB infections.
